Eur Rev Med Pharmacol Sci 2018; 22 (23): 8298-8305
DOI: 10.26355/eurrev_201812_16527

MiR-490-3p inhibited the proliferation and metastasis of esophageal squamous cell carcinoma by targeting HMGA2

N.-N. Kang, S.-L. Ge, R.-Q. Zhang, Y.-L. Huang, S.-D. Liu, K.-M. Wu

Department of Thoracic Surgery, 1st Affiliated Hospital of Anhui Medical University, Hefei, China. zbvz92@163.com


OBJECTIVE: To identify the potential role of miR-490-3p in the development of esophageal squamous cell carcinoma (ESCC), and to explore the possible underlying mechanism.

PATIENTS AND METHODS: Human ESCC tissues and cancer-adjacent normal tissues were collected. The mRNA expression level of miR-490-3p was detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). On-line target gene prediction software was applied to screen high-mobility group AT-hook 2 (HMGA2). Subsequently, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), qRT-PCR, Western blotting, transwell and scratch-wound assays were conducted to analyze the effect of miR-490-3p on the biological function of the ESCC cell line (EC-109).

RESULTS: In our study, the mRNA expression level of miR-490-3p was remarkably reduced in ESCC tissues and cells. Molecular mechanism analysis confirmed that miR-490-3p could act on the 3’-UTR of HMGA2 and regulate its expression. Subsequent functional experiments indicated that decreased expression of HMGA2 resulting from the up-regulation of miR-490-3p could inhibit the proliferation, invasion, migration and epithelial-mesenchymal transition (EMT) of ESCC cells.

CONCLUSIONS: We discovered the inhibitory effect of miR-490-3p on ESCC by targeting HMGA2, and revealed that miR-490-3p could be a potential therapeutic target for ESCC.

Free PDF Download

To cite this article

N.-N. Kang, S.-L. Ge, R.-Q. Zhang, Y.-L. Huang, S.-D. Liu, K.-M. Wu
MiR-490-3p inhibited the proliferation and metastasis of esophageal squamous cell carcinoma by targeting HMGA2

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 23
Pages: 8298-8305
DOI: 10.26355/eurrev_201812_16527